ArticleIntensive care medicine2009
Continued survival gains in recent years among critically ill myeloma patients.
Article in Intensive care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data.Intensive care medicine · 2019Pooled it
- Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data.Critical care (London, England) · 2018Pooled it
- Pooled it
- The use of high-flow nasal oxygen vs. standard oxygen therapy in hematological malignancy patients with acute respiratory failure in hematology wardsTurkish journal of medical sciences · 2021Trial
- Trial
- Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy.Intensive care medicine · 2010Trial
- Outcomes of critically ill patients with newly diagnosed Burkitt's lymphoma: a monocentric retrospective study.Annals of intensive care · 2026Article
- Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis.Annals of intensive care · 2026Article
- Parsimonious Subphenotyping Algorithms Perform Differently in Patients With Sepsis and Hematologic Malignancy.Critical care medicine · 2025Article
- Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.Journal of intensive medicine · 2025Article
- Management of hematological patients requiring emergency chemotherapy in the intensive care unit.Intensive care medicine · 2024Review
- Deep Learning-Based Early Warning Score for Predicting Clinical Deterioration in General Ward Cancer Patients.Cancers · 2023Article
- Article
- Oxygenation strategy during acute respiratory failure in immunocompromised patients.Journal of intensive medicine · 2021Review
- Acute Kidney Injury in the Patient with Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.Frontiers in medicine · 2021Review
- Impact of critical care response team implementation on oncology patient outcomes: A retrospective cohort study.International journal of critical illness and injury science · 2020Article
- The role of a critical care outreach service in the management of patients with haematological malignancy.Journal of the Intensive Care Society · 2019Article
- Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group.BMC infectious diseases · 2019Article
- Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTherapeutic advances have improved survival in patients with myeloma (MM) over the past decade. We investigated whether survival has also improved in critically ill myeloma patients.
designRetrospective study.
settingIntensive care unit. PATIENT: Consecutive myeloma patients admitted to a teaching hospital ICU between 1990 and 2006. We compared three year-of-admission groups (1990-1995, 1996-2001, and 2002-2006) that matched changes in myeloma treatment (chemotherapy only, stem cell transplantation, and new molecules, respectively).
interventionNone. MEASUREMENTS AND MAIN
resultsWe included 196 patients. Reasons for ICU admission and patient characteristics were similar across groups; however, less use of conventional chemotherapy and radiotherapy and greater use of steroids were noted in the more recent periods. Over time, vasopressors and invasive mechanical ventilation were used decreasingly, and noninvasive ventilation increasingly, to treat acute respiratory failure. Hospital mortality decreased from 75% in 1990-1995 to 49% in 1996-2001 and 40% in 2002-2006 (P = 0.0007). Mortality was associated with poor performance status [OR 2.27, 95% CI (1.04-4.99)], need for mechanical ventilation [OR 4.33, 95% CI (1.86-10.10)], need for vasopressors [OR 2.57, 95% CI (1.12-5.86)], and admission for an event related to myeloma progression [OR 2.77, 95% CI (1.13-6.79)]. ICU admission within 48 h after hospital admission was associated with lower mortality [OR 0.28, 95% CI (0.19-0.89)].
conclusionHospital mortality decreased significantly over the last 15 years in myeloma patients admitted to the ICU. Risk factors for death were organ failure and poor chronic health status. Early ICU admission was associated with lower mortality, suggesting opportunities for further improving survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.